Evaxion Non Currrent Assets Other from 2010 to 2024

EVAX Stock  USD 1.19  0.11  8.46%   
Evaxion Biotech Non Currrent Assets Other yearly trend continues to be fairly stable with very little volatility. Non Currrent Assets Other will likely drop to about 91.5 K in 2024. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
 
Non Currrent Assets Other  
First Reported
2010-12-31
Previous Quarter
167 K
Current Value
91.5 K
Quarterly Volatility
61.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Evaxion Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evaxion Biotech's main balance sheet or income statement drivers, such as Interest Income of 1.4 M, Depreciation And Amortization of 330.1 K or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 206, Dividend Yield of 0.0 or Days Sales Outstanding of 4.3 K. Evaxion financial statements analysis is a perfect complement when working with Evaxion Biotech Valuation or Volatility modules.
  
Check out the analysis of Evaxion Biotech Correlation against competitors.

Latest Evaxion Biotech's Non Currrent Assets Other Growth Pattern

Below is the plot of the Non Currrent Assets Other of Evaxion Biotech AS over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Evaxion Biotech's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evaxion Biotech's overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other10 Years Trend
Slightly volatile
   Non Currrent Assets Other   
       Timeline  

Evaxion Non Currrent Assets Other Regression Statistics

Arithmetic Mean33,168
Geometric Mean5,986
Coefficient Of Variation185.14
Mean Deviation49,979
Median(2,000)
Standard Deviation61,407
Sample Variance3.8B
Range169K
R-Value0.74
Mean Square Error1.8B
R-Squared0.55
Significance0
Slope10,224
Total Sum of Squares52.8B

Evaxion Non Currrent Assets Other History

202491.5 K
2023167 K
2022156 K
202193 K
2018 2000.0

About Evaxion Biotech Financial Statements

Evaxion Biotech investors use historical fundamental indicators, such as Evaxion Biotech's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Evaxion Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Currrent Assets Other167 K91.5 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Evaxion Stock Analysis

When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.